Skip to main content

Endophthalmitis Postoperative

0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Santen
SantenCA - Emeryville
2 programs
Levofloxacin OphthalmicPHASE_1_21 trial
Levofloxacin Ophthalmic ProductPHASE_1_21 trial
Active Trials
NCT04212078Unknown138Est. Oct 2022
NCT04212429Unknown128Est. May 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SantenLevofloxacin Ophthalmic Product
SantenLevofloxacin Ophthalmic

Clinical Trials (2)

Total enrollment: 266 patients across 2 trials

NCT04212429SantenLevofloxacin Ophthalmic Product

The Clinical Safety of Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%

Start: Sep 2019Est. completion: May 2022128 patients
Phase 1/2Unknown
NCT04212078SantenLevofloxacin Ophthalmic

Intracameral Levofloxacin (0.5%) vs Intracameral Cefuroxime

Start: Jul 2019Est. completion: Oct 2022138 patients
Phase 1/2Unknown

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.